UK Sleep-Wake Disorder Market Trends, Size, Competitive Analysis and Forecast 20

Posted by mansi on March 27th, 2020

The UK sleep-wake disorder market is estimated to grow at a CAGR of 6.2% during the forecast period. UK contributes a considerable share in the market due to the presence of a significant number of people with behavioral health disorders and the growing awareness of sleep disorders in the country. Mental Health First Aid (MHFA) England is a social organization that offers expert guidance and training to support mental health. According to the MHFA statistics 2019, 1 in 4 people faces mental health issues each year and responsible for 72 million working days lost and costs .5 billion each year. Additionally, 1 in 6 workers experience depression, anxiety or problems relating to stress at any one time and 526,000 cases of work-related stress, depression or anxiety were recorded in 2016-2017 in Great Britain as per MHFA.  In 2016-2017, stress was responsible for 40% of all cases of work-related ill health and for 49% of all working days lost due to health issues in the country as per MHFA. Therefore, work-related stress raises the risk of sleep disorders that further increases the demand for effective treatment.  

Request a Free Sample of our UK Sleep-Wake Disorder Market:

The market is segmented on the basis of type and treatment. Based on type, the market is sub-segmented into insomnia, hypersomnia, sleep apnea, circadian rhythm disorders, and others. Sleep apnea holds the largest market share during the forecast period. On the basis of treatment, the market is divide into therapies, drugs, and devices. The sleep-wake disorder devices segment is estimated to hold the largest market share during the forecast period, followed by medications. Some of the players operating in the market include Koninklijke Philips N.V, Medtronic PLC, Sanofi SA, Jazz Pharmaceutical Inc., and others.

 A full Report of UK Sleep-Wake Disorder Market is Available at:

In January 2020, Jazz Pharmaceuticals, SK Biopharmaceutical’s US partner received sales approval from the European Medicine Agency (EMA) for Sunosi (Ingredient: solriamfetol), a treatment for improving wakefulness in patients suffering from excessive daytime sleepiness related with narcolepsy or obstructive sleep apnea. SK Biopharmaceutical discovered Sunosi and completed its phase 1 clinical trial before licensing out the substance to Aerial BioPharma in 2011. Thereafter, Jazz Pharmaceuticals took over the global commercialization rights, including the US and Europe, for completing the phase 3 clinical trials for the drug. With this approval, Jazz Pharma has planned to launch Sunosi in Germany in mid-2020 and then to France and UK by early 2021.

UK Sleep-Wake Disorder Market Segmentation

By Type

  • Insomnia
  • Hypersomnia
  • Circadian Rhythm Disorders
  • Others

By Treatment

  • Therapies
  • Drugs
  • Devices

Company Profiles

  • Arena Pharmaceuticals, Inc.
  • Acorda Therapeutics, Inc.
  • Jazz Pharmaceuticals Inc.
  • Koninklijke Philips N.V.
  • LivaNova PLC
  • Medtronic PLC
  • Natus Medical Inc.
  • Pfizer Inc.
  • Sanofi SA
  • SomnoMed AG


About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.


Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari


Contact no: +1 646-755-7667, +91 7803040404

Like it? Share it!


About the Author

Joined: January 22nd, 2020
Articles Posted: 169

More by this author